Novel 3D Myeloma Organoid to Study Disease Biology and Chemosensitivity

Overview

The objective of this project is to compare chemosensitivity between chemotherapy combinations in bone marrow aspirates using 3D organoid models. The investigators overarching hypothesis is that 3D organoids are ideal to test chemosensitivity in real time, to provide personalized medicine and guidance in the setting of relapsed multiple myeloma and potentially other cancers.

SparkCures ID 1029
Trial Phase Observational Trial
Enrollment 40 Patients
Trial Sponsors
  • Wake Forest University Health Sciences
Trial Collaborators
  • National Cancer Institute (NCI)
NCT Identifier

NCT03890614

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Patients with suspected or confirmed multiple myeloma undergoing a bone marrow biopsy as part of their care.
  • The ability to understand and willingness to sign an IRB approved informed consent document.

Exclusion Criteria:

  • They must not have other known active hematologic malignancies or amyloidosis.
  • Any participant that does not have multiple myeloma.

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.

SparkCures Verified Accurate, up-to-date information. Learn more

North Carolina
Verified Wake Forest Baptist Comprehensive Cancer Center Wake Forest School of Medicine

SparkCures Verified Accurate, up-to-date information. Learn more

Resources

There are no resources, links or videos to display for this clinical trial.